Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
FDA
The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.
Three companies have posted major developments in the field of heart disease therapy.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Flagship Pioneering Founder and CEO Noubar Afeyan has been behind the launch of dozens of companies, some of which, such as Moderna, have become a household name across the globe.
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
Moderna responded to claims that the government should be co-patent owners of the mRNA vaccine developed by the company and said its mRNA sequence was exclusively selected by Moderna scientists.
JOBS
  • 2025 Hotbed Maps - Genetown - Elite - Moderna.png
IN THE PRESS